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reimbursement methods, HTAs at the national level are more common.
CONCLUSIONS: Basic drivers of market access, such as health care spend, financ-
ing structure and regulatory policy create both independent and interdependent
mechanisms that support access to new device technologies. Consideration of
country level conditions and hurdles will inform device manufacturers’ differential
strategies to enter established and emerging markets.
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STAKEHOLDER INVOLVEMENT IN HEALTH TECHNOLOGY ASSESSMENT (HTA)
OF NOVEL MEDICAL DEVICES
Hidefjall P
KTH Royal School of Technology, Huddinge, Huddinge, Sweden
HTA for medical devices follows the path of drugs in many countries. There are
however substantial differences that should be considered when evaluating med-
ical devices. Drummond (2009) describes six important differences. Medical de-
vices: 1) are often diagnostic therefore requiring to consider their related therapeu-
tic effects; 2) have faster product cycles often making trial results outdated; 3)
performance depend on users’ skills and complementary investments in training
and equipment; 4) innovation may cause a shift from one in-patient setting (oper-
ating room) to another (cathlab) or to an out-patient setting with substantial cost-
effects; 5) are manufacturer specific, making it difficult to draw conclusions about
product class effects; 6) innovation may be difficult to protect with patents thus
encouraging imitation with resulting falling prices. In addition to issues 1-6, regu-
latory approval of a device does not require the same level of evidence as for drugs.
Despite initial poor evidence, decisions on health care resource-use based on cost-
utility (QALY) need to be made throughout the product lifecycle. This can be
achieved by involving stakeholders in regular, timely data exchange for model
updating, considering issues 1-6 above. As medical devices directly affect several
stakeholders, their respective treatment costs from accounting systems can be
used (4). As product registries are continuously updated the improving perfor-
mance due to new devices and user learning is reflected (2-3). According to regu-
latory requirements manufacturers must evaluate their product performance and
notify competent authorities of adverse events. Such data should update cost-
utility evaluations relating to manufacturer specific patient morbidity (5). Further-
more as outcomes data are increasingly captured by devices directly or apps and
electronically transferred to electronic health records, the burden on manufactur-
ers to administrate registries may be lessened (2). As medical devices are regularly
procured in tenders, their product prices should be used (6). In turn HTA outcomes
should inform tenders.
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OPPORTUNITIES AND LIMITATIONS OF SUSTAINABILITY INDICES IN
SATISFYING THE NEEDS OF HEALTH TECHNOLOGY PURCHASERS SEEKING
OBJECTIVE AND UNBIASED INDICATORS OF ENVIRONMENTAL AND SOCIETAL
IMPACTS
Wright AJ, Froehlich HJ
PHMR Associates, London, UK
OBJECTIVE: To establish the extent to which existing sustainability indices provide
pertinent and transparent evidence of the environmental and social impacts of
health technology providers. METHOD: A search was undertaken to identify a
comprehensive list of sustainability indices for study. For each of these the follow-
ing criteria were identified; target constituency, specific environmental or social
domains being measured, criteria for inclusion, data sources and ranking or scor-
ing methodology. RESULTS: The majority of indices were found to be focused on
the needs of investors rather than purchasers. The indices either measured specific
environmental or social domains such as carbon efficiency, water risks and social
impacts, or provided a broader measure of sustainability by combining environ-
mental, social and governance issues together in a single metric. Incorporation
within an index often required inclusion in pre-existing non sustainability criteria
against which additional sustainability measures were applied. Data used within
the indexes reviewed were found to have been derived from publically available
sources such as websites and company reports, or from data submitted by the
organisations under evaluation to rating research groups. Few of the indices pub-
lished a level of methodological transparency that could provide sufficient visibil-
ity in order to understand how they are derived. CONCLUSION: There remains a
latent need among purchasers for a verifiable method of measuring sustainability
of providers. In order for a sustainability index to provide utility in the comparison
of health technology providers the following criteria must be met; The index
should be open to all Health Technology providers, methods used by the index to
measure performance should be transparent. None of the current sustainability
indexes reviewed fulfilled these criteria. Further study is needed to identify the
environmental and social domains of importance to purchasers and the best ap-
proach for deriving this data.
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FROM SCIENCE TO SERVICE: THE ONTARIO PATIENT REPORTED OUTCOMES OF
SYMPTOMS AND TOXICITY (ON-PROST) RESEARCH UNIT
Howell D, Perez Cosio A, Liu G, Rodin G, Hope A
University Health Network, Toronto, ON, Canada
Research suggests that routine collection of Patient Reported Outcome Measures
(PROMs) can contribute to clinical decision-making and improve health, but their
systematic implementation in Ontario, outside the Edmonton Symptom Assess-
ment (ESAS), has not yet occurred. While ESAS is a valid symptom screening tool, it
does not allow customization to disease specific symptoms or toxicities nor does it
reflect the multidimensional impact of cancer on physical, emotional and social
health. Reaching consensus on a core set of PROMS for each of these domains is
critical to improving health and monitoring the impact of cancer. However, apply-
ing numerous PROMs is burdensome to patients and evaluators. We are now mov-
ing forward to make routine PROM data collection a reality in the cancer system.
On-PROST aims to improve the patient experience of cancer and the quality of care
through the routine collection of a standardized set of (PROMs) for use in clinical
care, and to advance the science of cancer treatment through research across the
cancer continuum. Based on initial consensus for the implementation of core
PROM data (PROMs-Cancer Core), we will develop a cohesive research agenda and
foster the development, standardization and implementation of core PROMs rele-
vant across cancer populations for research use and clinical practice. On-Prost
focuses on five cancer research areas: Health Services Research; Biomarker Re-
search; Radiation Oncology; Palliative and Supportive Care; and the PROMs-Cancer
Core items. We plan to develop national and international partnerships, and to
foster the development, standardization and implementation of core PROMs rele-
vant across cancer populations and for disease specific purposes for routine clinical
care and trials. Our goal is to foster common PROMs with multiple purposes, in-
cluding performance and impact of cancer reporting, that will help deliver person-
alized quality care and treatment, and will concretely impact on cancer control and
policy over the next five years.
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THE IMPACT OF THE GERMAN PHARMACEUTICAL MARKET REORGANISATION
ACT (AMNOG) ON THE GERMAN REFERENCE PRICE MARKET – TRENDS TWO
YEARS AFTER THE INTRODUCTION OF THE AMNOG
Eheberg D1, Batscheider A1, Lebioda A1, Plantör S1, Fricke FU2
1IMS Health GmbH & Co. OHG, Munich, Germany, 2IMS Health GmbH & Co. OHG, Nuremberg,
Germany
With the introduction of the German Pharmaceutical Market Reorganisation Act
(German: “Arzneimittelmarktneuordnungsgesetz” (AMNOG)) in January 2011,
pharmaceutical entrepreneurs have to present a dossier to demonstrate the addi-
tional benefit of a new pharmaceutical at product launch in the German market.
Pharmaceuticals failing to demonstrate additional benefit against the standard of
care in the corresponding indication can be included in an existing reference price
group or even trigger the building of a new one. Top-selling reference price markets
with many newcomers or price-aggressive competitors are at risk of a repeated
examination through the federal joint committee (G-BA) in short intervals, result-
ing in a frequent updating of the reference price. This triggers a cascade, the so
called “Kellertreppeneffekt” (Race to the Bottom), which could result in a rapidly
decreasing reference price. One parameter of interest to assure an adequate secu-
rity of supply is the measure value 160, assuring that at least 20% of packages and
20% of prescriptions are available at a lower price than the new reference price. To
avoid the cascade, alternative, lower measure values, such as the measure value
100, can be applied. The measure value 100 is feasible for reference price groups
with a large amount of products which are free of patients’ copayment. Pharma-
ceuticals are normally free of patients’ copayment if the product price is 30% lower
than the corresponding reference price. The focus of our presentation is to analyze
the impact of the AMNOG on 10 top-seller reference price groups and to evaluate
further adjustments to the reference price level of these groups through varying
measure values. Furthermore, additional parameters of interest influencing the
reference price level will be considered.
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EFFECTIVE DEMAND FOR A HEALTH LITERATE HEALTH CARE SYSTEM -
EVIDENCE FROM IRISH SURVEY DATA
Coughlan D
National University of Ireland, Galway, Galway, Ireland
Health literacy (HL) research has mainly focused on the skills and abilities of indi-
viduals in the health care setting. For the past 20 years, most research has been
conducted in North America. However, HL is now gaining political support at Eu-
ropean Union level. This presentation is concerned with attitudes that nationally
representative survey respondents in Ireland have towards improving their health
by seeking a more health literate health care system. Two waves of the Survey of
Lifestyle, Attitudes and Nutrition (SLAN 1998 & 2002) were used in this analysis.
The primary focus of this study was to look across the socioeconomic gradient and
see whether Irish health policymakers should invest in HL as a health inequalities
or a public health issue. A secondary objective was to look at preventive health care
utilization (General health check-up, blood pressure check-up, blood cholesterol
check-up) using the HL variable as the main independent variable stratified by
gender and medical card eligibility.
The constructive dependent variable (termed ‘effective demand for a health liter-
ate health care system’) showed that 46% of respondents desired at least one at-
tribute on a health literate health care system. Various multivariate logistic regres-
sion models used social class grouping, medical card eligibility, level of education
and employment status as the main socioeconomic gradient variables. No discern-
ible trend emerged among the socioeconomic variables. This suggests that HL
should be viewed as a public health issue with a policy focus at a system level.
Consistently, females (OR 1.15; 95%:1.04 -1.28) were more likely than males to seek a
health literate health care system. However, males without a medical card with an effec-
tive demand for health literate health care system were more likely to get a general
check-up (OR 1.23; 95%:1.03 -1.47). The investment in making the system more user-
friendly would benefit all in society and not those stigmatized as having low literacy.
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CAN RISK MANAGEMENT PLANS (RMP) CONTRIBUTE TO HEALTH TECHNOLOGY
ASSESSMENT (HTA) AND KNOWLEDGE OF SAFETY IN EVERYDAY MEDICAL
PRACTICE?
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The marketing authorisation of a new medicine is granted on the basis of a favor-
able benefit-risk balance for its target population and indication. However, not all
risks will have been identified at the time when an initial authorisation is sought
and many of the risks associated with the use of a medicinal product will only be
discovered/fully characterised when the medicine is widely used in everyday med-
ical practice. A full HTA should provide for an evaluation of adverse drug reactions
(ADR) including those identified during long term follow- up or which are rare. In
addition to knowledge of risks, a relevant consideration for both individual pa-
tients and policy makers is the performance of risk minimization measures (RMM)
in everyday medical practice. The new European pharmacovigilance legislation
embeds the RMP as a key tool in proactive pharmacovigilance. The RMP, as the
documented set of pharmacovigilance activities and interventions designed to
identify, characterise, and prevent/minimise risks associated with exposure to a
medicine, may include specific RMM. RMM should be shown to achieve the desired
effect of reducing the burden of ADR and optimising health outcomes. Implemen-
tation of RMM may involve a substantial investment of resources and their perfor-
mance in health care systems should be assessed. In case a RMM proves ineffective,
alternative interventions must be identified implemented. We introduce an ap-
proach to evaluating the effectiveness of RMM that builds on the assessment of two
distinct levels of evidence. The evaluation of the effectiveness of RMM should
differentiate between the actual implementation of the RMM, and the attainment
of its final objective(s). If the RMM is unsuccessful, this strategy will help to ascer-
tain whether the intervention was inherently ineffective or badly delivered. The
assessment requires research encompassing analysis of implementation (process
indicators), and traditional epidemiological research addressing the attainment
(final outcome indicators) of RMM.
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BRIDGING THE GAP BETWEEN INSTITUTIONAL LEVELS USING SYSTEMS
ANALYSIS
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1McMaster University, Hamilton, ON, Canada, 2PATH Research Institute, McMaster University,
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Transforming the provision of health care involves collaboration and change on
many levels. Too often health care delivery decisions are made without consider-
ing the complex and dynamic nature of the health system. Approaching these
problems from a systems thinking perspective integrates these traits and encour-
ages long term thinking about solutions. Despite being widely used in other disci-
plines, only recently has systems analysis started to play a larger role in transform-
ing health care provision. The purpose of this work is to outline how systems
analysis tools can bridge multiple levels of health care to make more informed
decisions. The aforementioned will be illustrated using a Canadian case study.
Currently, a provincial strategy to diagnose and treat epilepsy in adults and chil-
dren in Ontario is being examined. The organization of epilepsy specific care cen-
tres (ESCC) into district and regional services is being recommended which will
modify current practice patterns and access to care. Subsequently, any changes in
delivery will have an impact on referral rates and patterns as well as resource
utilization (i.e. beds, staff, and diagnostic tests). The use of systems analysis tools
can bring insight into how the inter-relationship between ESCCs can be modeled
and how access to care will be affected and aid in capacity planning (i.e. resources
and costs).System changes can be graphically illustrated and quantified using the
systems analysis tool discrete event simulation. Mapping the clinical pathways
and patient flow of epileptic patients through the current system, a simulation
model was developed to help inform the planning process. This was useful in
understanding how the system might respond and in identifying potential bottle-
necks or where resources may be limited. Using discrete event simulation facili-
tated the ability to take on multiple perspectives by conducting analyses at multi-
ple institutional levels (i.e. government, hospital and health care practitioner).
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HOW TO OPTIMISE CHANCES FOR SUCCESSFUL AMNOG ASSESSMENTS – BEST
PRACTICE APPROACH FOR GERMAN MARKET ACCESS
Bonduelle D, Plantoer S
IMS GmbH & Co. OHG, Munich, Bavaria, Germany
Since the introduction of AMNOG in January 2011, manufacturers in Germany are
required to submit a “benefit dossier” and show additional benefit in relation to a
so-called appropriate comparative therapy to the Federal Joint Committee for every
NCE in order to gain access to price negotiations. If an additional benefit is shown,
the new reimbursed price will be a surplus on the reimbursed comparator price.
Market access in Germany changed significantly due to AMNOG and requires early
preparation, an interdisciplinary approach and clearly defined internal processes.
Market access strategies and processes have to be reviewed in light of the new
framework and adapted in order to optimize the chance to be successful in the
AMNOG process. Preparation for AMNOG should start as early as in the planning of
clinical studies to implement the right questions into the study and not to rely on
surrogate drivers. The FJC will respond best to data providing the most credible
scientific clinical evidence. Building RCTs powered to capture such information
does present important issues for pharmaceutical companies to address. Early
planning of clinical studies should be part of an early strategy development for the
NCE that can be informed by early phase modeling of the likely outcome of the
benefit assessment. Early identification of the patient groups that are most likely to
benefit is vital in order to plan for patient (sub-) populations big enough to achieve
statistical significant results and positive outcomes in the AMNOG process. An
interdisciplinary approach is required at a stage in the product development where
there are no common processes and communication paths established between
headquarter and affiliates. A best practice approach requires a well defined process
including road maps and checklists per stage of product development in form of
standard operating procedures in order to optimize market access.
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APPROPRIATE METHODS FOR ECONOMIC EVALUATION OF PROGRAMMES
WITH COSTS AND EFFECTS EXTENDING ACROSS SECTORS
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Public policies/interventions impact on many areas of activity including areas be-
yond the main focus of them ; the costs and (dis)benefits falling on other areas of
the economy, government and/or private sector, and different individuals. How-
ever, there is no consensus on the appropriate way to analyse such policies/inter-
ventions to decide which are beneficial and should be implemented. One form of
economic evaluation, cost-effectiveness analysis, has been widely used to inform
decisions about policies/interventions which affect only a single sector where
there is a single agreed output (as in most health care evaluations), however, its use
for evaluating interventions with multi-sector impacts is limited. Cost-benefit
analysis (CBA), another form of economic evaluation, based on welfarism, has been
proposed as a method which allows the evaluation of policies/interventions where
costs and benefits fall on several sectors, by aggregating costs and benefits into a
given numeraire, normally consumption. However, a key weakness of CBA is it fails
to acknowledge the relevance of sectors’ budget constraints. This despite the pro-
cess by which budget constraints are set being viewed as having (democratic)
legitimacy. We consider how decisions on policies/interventions with multi-sec-
toral impacts could most appropriately be informed by economic evaluation. Two
options are considered: first, where there is an implied or explicit social welfare
function (which could be based on welfarist or extra-welfarist principles); and
second, a societal decision making approach. We aim to demonstrate that trade-
offs are inevitable and have to be made, but budget constraints cannot be ignored
and shadow prices on budget constraints are central no matter which approach is
accepted. We also consider whether compensation payments between ‘losing’ and
‘gaining’ sectors are a potential means of understanding the net benefit associated
with policies with multi-sectoral effects, and whether it is possible, necessary or
even appropriate in practice to make such payments.
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PRIMARY CARE TRANSFORMATION AS A SOLUTION TO THE EPIDEMIC OF
CHRONIC DISEASES
Carrera P
University of Twente, Enschede, The Netherlands
That the world faces an epidemic of chronic diseases is unmistakable. Chronic
diseases represent 63% of all deaths worldwide. Against the background of demo-
graphic aging, the prevalence of comorbidity or multi-morbidity is as high as 60%
among individuals aged 55 to 74 years. In the context of financial crunch wrought
by the financial crisis, the financial and non-financial burden of chronic diseases
make their management a priority concern globally. Primary care plays a critical
role in dealing with this epidemic. To harness the full potential of primary care,
however, the way it is organized needs transformation. At present 1) primary care
is still organized around the primary care physician even as the shortage of pri-
mary care physician is worsening and is unlikely to improve in the immediate
future; 2) models of care for the chronically ill are directed to the management of
each disease separately, and despite its attribute of continuity, comprehensiveness
and patient-centeredness; 3) fails to harness the contribution of patient self-man-
agement even as role of patient involvement in their health and health care is
recognized; and 4) and overcome the barriers resulting from the structure of the
health care system. These challenges are true for primary care in low and middle-
income settings and high-income settings. A global framework for the transforma-
tion of primary care, consequently, offers promise to every health care system. The
critical elements of such involve 1) the development of primary care teams that
include physician services extenders such as primary care physicians or nurse
practitioners; 2) that will deal with the health needs of the population – rather than
the those of the individual patient; 3) by way of engaging chronically ill patients in
co-managing their condition; 4) using ehealth technologies and point-of-care-test-
ing facilities.
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ASSESSING THE VALUE OF ACCESS TO INDIVIDUAL PATIENT DATA FOR
REIMBURSEMENT DECISIONS
Manca A
University of York, Heslington, York, UK
To successfully support health care decision-making, cost-effectiveness analysis
(CEA) must consider and synthesise all (relevant) available evidence relating to the
clinical effectiveness, health-related quality of life (HRQoL) and costs of the health
technologies under scrutiny. Evidence based medicine tells us that statistical evi-
dence synthesis of multiple individual patient level data (IPD) sources (e.g. IPD
meta-analysis and its extensions) is the gold standard for deriving relative treat-
ment effect estimates, one of the key parameters in any cost-effectiveness model.
Unfortunately the evidence base available to the cost-effectiveness modeller is
often multifaceted and fragmented, comprising a mix of aggregate (AD, or sum-
mary level) and individual patient level data. This scenario poses a series of meth-
odological issues and it is not uncommon for the analyst to end up collapsing the
IPD into AD, with consequent loss of information, for use in a standard evidence
synthesis model (e.g. meta analysis or mixed treatment comparison of AD). Such a
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